Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jan;47(1):148-53.
doi: 10.1128/AAC.47.1.148-153.2003.

Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns

Kenneth E Aldridge  1 , Deborah Ashcraft, Megan O'Brien, Charles V Sanders
Affiliations

Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns

Kenneth E Aldridge et al. Antimicrob Agents Chemother. 2003 Jan.

Abstract

A retrospective analysis of susceptibility data on 542 blood isolates of the Bacteroides fragilis group tested from 1987 to 1999 by the same NCCLS-recommended broth microdilution method throughout is presented. Metronidazole, beta-lactam-beta-lactamase inhibitor combinations, carbapenems, and trovafloxacin were the most active agents (susceptibility of >or=93%). Among the cephalosporin-cephamycins, the order of activity was cefoxitin > ceftizoxime > cefotetan = cefotaxime = cefmetazole > ceftriaxone. All isolates were resistant to penicillin G, and 22% were resistant to clindamycin. The susceptibility rates to piperacillin-tazobactam, imipenem, and meropenem were affected least among isolates resistant to cefoxitin or clindamycin. Except for piperacillin-tazobactam, imipenem, and meropenem, the B. fragilis species was more susceptible than were the non-B. fragilis species. These data underscore the importance of susceptibility testing of the B. fragilis group and can serve as a guide in the choice of empirical antimicrobial therapy.

PubMed Disclaimer

References

    1. Aldridge, K. E., C. V. Sanders, A. C. Lewis, and R. L. Marier. 1983. Susceptibility of anaerobic bacteria to beta-lactam antibiotics and beta-lactamase production. J. Med. Microbiol. 16:75-82. - PubMed
    1. Aldridge, K. E., A. Henderberg, D. D. Schiro, and C. V. Sanders. 1988. Susceptibility of Bacteroides fragilis group isolates to broad-spectrum β-lactams, clindamycin, and metronidazole: rates of resistance, cross-resistance, and importance of β-lactamase production. Adv. Ther. 5:273-282.
    1. Aldridge, K. E. 1992. In vitro susceptibility of Bacteroides fragilis group strains from abscesses, body fluids, and wound/tissue sources. Drug Investig. 4(Suppl. 1):1-6.
    1. Aldridge, K. E. 1993. Activity of β-lactam-β-lactamase inhibitor combinations against the Bacteroides fragilis group: increased resistance among B. distasonis strains, p. 478-479. In Proceedings of the 18th International Congress of Chemotherapy. International Congress of Chemotherapy, Stockholm, Sweden.
    1. Aldridge, K. E., M. Gelfand, L. B. Reller, L. W. Ayers, C. L. Pierson, F. Schoenknect, R. C. Tilton, J. Wilkins, A. Henderberg, D. D. Schiro, M. Johnson, A. Janney, and C. V. Sanders. 1994. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamycins, penicillins, clindamycin, and metronidazole in the United States. Diagn. Microbiol. Infect. Dis. 18:235-241. - PubMed

MeSH terms

LinkOut - more resources